CWRU and UTMC-linked Rodeo Therapeutics is set to be acquired by Amgen for $55m in upfront and up to $666m in milestone payments.

Rodeo Therapeutics, a US-based small-molecule therapy developer based on research at Case Western Reserve University and University of Texas Southwestern Medical Center, has agreed to an acquisition by pharmaceutical firm Amgen for up to $721m.
Amgen will pay an initial $55m and up to $666m in cash subject to milestones.
Rodeo is developing small-molecule therapies, including its lead 15-prostaglandin dehydrogenase (15-PGDH) modulators, that will help regenerate and repair various types of tissue, for use in dealing with conditions such as…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
James Mawson

James Mawson is founder and chief executive of Global Venturing.
email
Linked in